Management ChangeApr 30, 2026, 07:03 AM
LXEO Appoints Dr. Laura Sepp-Lorenzino to Board
AI Summary
Lexeo Therapeutics, Inc. announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. Dr. Sepp-Lorenzino will serve until the 2028 Annual Meeting of Stockholders and join the Science and Technology Committee. Her compensation includes $40,000 in annual cash, an initial grant of 50,000 stock options, and future annual options for 25,000 shares starting in 2027. She brings extensive experience from previous roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam, and Merck.
Key Highlights
- Dr. Laura Sepp-Lorenzino appointed to Lexeo Therapeutics' Board of Directors on April 28, 2026.
- Her term of office expires at the Company’s 2028 Annual Meeting of Stockholders.
- Dr. Sepp-Lorenzino was also appointed as a member of the Science and Technology Committee.
- She is eligible for $40,000 in annual cash compensation for Board service.
- An initial stock option award for 50,000 shares was granted on the appointment date.
- She is expected to receive an annual option to purchase 25,000 shares starting in 2027.
- Dr. Sepp-Lorenzino, age 65, has served as Principal of GNMmeds LLC since January 2025.
- She previously served as Executive VP, Chief Scientific Officer of Intellia Therapeutics from 2019 to 2025.
Price Impact
More from LXEO